NCT07264010

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for Measurable Residual Disease Persisting Acute Myeloid Leukemia: a Prospective, Single-arm, Multicenter Clinical Study

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 87 (estimated)
• Sponsor: Nanfang Hospital, Southern Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.

Conditions

• Acute Myeloid Leukaemia (AML)
• Measurable Residual Disease (MRD)

Interventions

Type	Name	Description
DRUG	Sorafenib (SORA)	Sorafenib (SORA) was administered at 400mg twice daily on days 1 to 28.
DRUG	Venetoclax (VEN)	Venetoclax (VEN) was administered at 400mg/day on days 1 to 28.

Timeline

• Start date: 2025-12-01
• Primary completion: 2026-12-30
• Completion: 2028-12-30
• First posted: 2025-12-04
• Last updated: 2025-12-04